Revolution Medicines (RVMDW) Free Cash Flow (2019 - 2026)

Revolution Medicines' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$355.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 79.98% year-over-year to -$355.0 million; the TTM figure through Mar 2026 stood at -$1.1 billion (down 79.84% YoY), while the FY2025 annual figure was -$913.7 million, down 63.45% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$355.0 million, down from -$277.5 million in the prior quarter.
• The five-year high for Free Cash Flow was -$51.6 million in Q3 2022, with the low at -$355.0 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$130.8 million (2024), against an average of -$141.6 million.
• Peak annual rise in Free Cash Flow reached 11.05% in 2024, while the deepest fall reached 154.11% in 2024.
• Revolution Medicines' Free Cash Flow stood at -$61.3 million in 2022, then sank by 92.17% to -$117.8 million in 2023, then retreated by 11.05% to -$130.8 million in 2024, then sank by 112.2% to -$277.5 million in 2025, then declined by 27.91% to -$355.0 million in 2026.
• Business Quant data shows RVMDW's Free Cash Flow at -$355.0 million in Q1 2026, -$277.5 million in Q4 2025, and -$209.3 million in Q3 2025.